CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

49.01 -0.38 (-0.77%)

Delayed Quote Updated: 4:00 PM EDT, Oct 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2

...

19 20 21 22 23 24 25 26 27

...

37 38 Next >

3 Growth Stocks With 55% to 71% Upside, According to Wall Street ↗

July 09, 2023

Find out why investment bank analysts are so bullish on these stocks.

Via The Motley Fool

2 Growth Stocks That Might Be Too Cheap to Ignore ↗

July 06, 2023

The sky is the limit for these healthcare companies.

Via The Motley Fool

Thoughts For Thursday: Back From The Holiday With Caution ↗

July 06, 2023

Caution is perhaps what was reflected in yesterday's back from the holiday trading. One there is the question of upcoming Fed action and second there is the visit of Secretary Yellen to China.

Via Talk Markets

3 Biotech Stocks That AI Predicts Will Deliver Triple-Digit Returns in 2025 ↗

July 05, 2023

In researching this article, we used AI to help make predictions for potential triple-digit return biotech stocks by 2025

Via InvestorPlace

Cathie Wood Continues To Sell Tesla Shares Amid Q2 Deliveries-Induced Strength: Here's How Much Shares Ark Offloaded Monday ↗

July 03, 2023

Via Benzinga

Vertex Pharmaceuticals Stock: Bear vs. Bull ↗

July 03, 2023

Vertex has reached a key moment in its story.

Via The Motley Fool

2 Under-the-Radar Biotech Stocks to Buy in 2023 ↗

June 28, 2023

These companies are coming into their own.

Via The Motley Fool

3 Stocks That Every 20-Year-Old Should Buy Today ↗

July 02, 2023

When you’re just starting out in adult life, you have time on your side. Use it to your advantage with these stocks for young investors.

Via InvestorPlace

The 3 Most Undervalued Biotech Stocks to Buy Now: June 2023 ↗

June 29, 2023

If you dig deep enough, you’ll find some undervalued biotech stocks with substantial catalysts straight ahead.

Via InvestorPlace

This 1 Problem Could Sink at Least 4 Gene-Editing Stocks ↗

June 29, 2023

Reaching profitability could be harder than investors expect.

Via The Motley Fool

2 Unstoppable Growth Stocks to Buy in 2023 and Beyond ↗

June 29, 2023

Both companies have therapies that should help grow revenue and earnings for years.

Via The Motley Fool

The Best Stocks to Invest $20,000 in Right Now ↗

June 28, 2023

You can invest in these companies with $20,000 -- or even a lot less.

Via The Motley Fool

Why Shares of Nkarta Are Slumping Tuesday ↗

June 27, 2023

The pharmaceutical stock dropped after announcing so-so clinical trial results.

Via The Motley Fool

Is CRISPR Therapeutics Stock a Buy Now? ↗

June 21, 2023

CRISPR stock has climbed more than 40% so far this year.

Via The Motley Fool

Where Will CRISPR Therapeutics Be in 10 Years? ↗

June 14, 2023

The biotech is part of a revolution in gene-editing therapies.

Via The Motley Fool

Wall Street Estimates That CRISPR Therapeutics Stock Could Jump 49%. Here's Why That's Right. ↗

June 27, 2023

With two huge catalysts drawing near, its stock could go even higher.

Via The Motley Fool

What Is CRISPR And Why Should Your Portfolio Care? ↗

June 25, 2023

CRISPR Therapeutics continues to be at the forefront of CRISPR-based therapeutics development. It's the first, and largest, but not the only player.

Via Talk Markets

3 Monster Stocks in the Making to Buy Right Now ↗

June 25, 2023

They're not monsters now -- but just give them some time.

Via The Motley Fool

Alleged Industrial Espionage Makes an Interesting Story ↗

June 21, 2023

We also chat about Vertex Pharmaceuticals and its role at the center of cystic fibrosis treatment.

Via The Motley Fool

Cathie Wood Is Buying This Growth Stock and Selling Its Competitor. Should You Follow Suit? ↗

June 21, 2023

There's more than one reason to sell a stock while buying another.

Via The Motley Fool

Buying This Growth Stock Hand-Over-Fist Right Now Could Make You a Lot Wealthier by 2030 ↗

June 21, 2023

This company has several catalysts for growth coming up, with more on the way.

Via The Motley Fool

3 Millionaire-Maker Biotech Stocks to Buy and Hold Forever ↗

June 20, 2023

Here are three long-term biotech stock investments that have the opportunity to turn risk -tolerant investors into millionaires.

Via InvestorPlace

Here's the Secret Behind Cathie Wood's Latest Moneymaking Strategy ↗

June 18, 2023

Success could be in the DNA of the Ark Invest founder.

Via The Motley Fool

How Biotech Stocks Are Revolutionizing Healthcare Investment Opportunities ↗

June 17, 2023

The field of biotechnology has become a driving force behind groundbreaking medical advancements, offering investors the opportunity to benefit from these innovations. Here are 10 healthcare innovators...

Via Talk Markets

3 Cathie Wood Investments That Could Deliver Superior Returns ↗

June 17, 2023

These three stocks fit Wood's profile for big-time growth.

Via The Motley Fool

2 Short-Squeeze Candidates That Could Go Parabolic ↗

June 15, 2023

Editas Medicine and Bluebird Bio have been favorite targets for short-sellers lately.

Via The Motley Fool

This Move Is a First for the FDA. Could It Signal a Big Turning Point for CRISPR Therapeutics? ↗

June 13, 2023

All eyes are on CRISPR Therapeutics' gene editing technology.

Via The Motley Fool

5 Stocks to Buy With Explosive 500% Potential ↗

June 12, 2023

Take advantage of a bullish change in investor sentiment with these five stocks to buy for 500% upside potential.

Via InvestorPlace

2 Biotech Stocks That Could Help Make You a Fortune ↗

June 12, 2023

Biotech stocks with cutting-edge therapies have the potential to generate substantial returns over time.

Via The Motley Fool

3 No-Brainer Stocks to Buy in June ↗

June 10, 2023

These biopharma stocks could be big winners.

Via The Motley Fool

< Previous 1 2

...

19 20 21 22 23 24 25 26 27

...

37 38 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.